Facebook Linkedin Twitter
Inside Precision Medicine Lucid Diagnostics’ Esophageal DNA Test Gets FDA Breakthrough Designation

Cervical cancer

Esophageal cancer, illustration
Molecular Dx

Lucid Diagnostics’ Esophageal DNA Test Gets FDA Breakthrough Designation

Chris Anderson -
0
Ovarian Cancer
Molecular Dx

Single-Cell Sequencing Provides Insights into Ovarian Cancer Subtypes

Chris Anderson -
0
Illustration of female reproductive system including uterus and ovaries to represent ovarian cancer
Molecular Dx

Ovarian Cancer Blood Test May Eliminate Need for Diagnostic Exploratory Surgery

Inside Precision Medicine Staff Writer -
0
Cervical Microbiome May Promote Cancer
Molecular Dx

Cervical Microbiome May Promote Cancer

Inside Precision Medicine Staff Writer -
0
Novacyt said today it is selling its NOVAprep® next-generation
Molecular Dx

Novacyt to Sell NOVAprep Cytology Solution, Clinical Lab Businesses

Inside Precision Medicine Staff Writer -
0
Agilent Technologies’ Dako PD-L1 IHC 22C3 pharmDx assay has become the first FDA-approved companion diagnostic to identify patients with cervical cancer for treatment with Merck & Co.'s cancer immunotherapy Keytruda (pembrolizumab). [Agilent Technologies]
Molecular Dx

Agilent CDx for Keytruda Gets FDA Approval for Cervical Cancer

Inside Precision Medicine Staff Writer -
0
Clinical OMICs Magazine Volume 1, Issue No. 11
News & Features

Clinical OMICs Magazine Volume 1, Issue No. 11

Inside Precision Medicine Staff Writer -
0
A recent report estimates the global demand for PCR technologies in 2013 to be around $10.6 billion. [Caleb Foster - Fotolia.com]
Molecular Dx

Expanding End-Use Segments Drive PCR Growth Worldwide

Syamala Ariyanchira, Ph.D. -
0
Clinical OMICs Magazine Volume 1, Issue No. 3
News & Features

Clinical OMICs Magazine Volume 1, Issue No. 3

Inside Precision Medicine Staff Writer -
0
1234Page 4 of 4

Related Content

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Inside Precision Medicine